Espejo-Roman, Jose MRubio-Ruiz, BelenCano-Cortes, VictoriaCruz-Lopez, OlgaGonzalez-Resines, SaulDomene, CarmenConejo-Garcia, AnaSanchez-Martin, Rosario M2023-05-032023-05-032022-04-01Espejo-Román JM, Rubio-Ruiz B, Cano-Cortés V, Cruz-López O, Gonzalez-Resines S, Domene C, et al. Selective Anticancer Therapy Based on a HA-CD44 Interaction Inhibitor Loaded on Polymeric Nanoparticles. Pharmaceutics. 2022 Apr 4;14(4):788.1999-4923http://hdl.handle.net/10668/21548Hyaluronic acid (HA), through its interactions with the cluster of differentiation 44 (CD44), acts as a potent modulator of the tumor microenvironment, creating a wide range of extracellular stimuli for tumor growth, angiogenesis, invasion, and metastasis. An innovative antitumor treatment strategy based on the development of a nanodevice for selective release of an inhibitor of the HA-CD44 interaction is presented. Computational analysis was performed to evaluate the interaction of the designed tetrahydroisoquinoline-ketone derivative (JE22) with CD44 binding site. Cell viability, efficiency, and selectivity of drug release under acidic conditions together with CD44 binding capacity, effect on cell migration, and apoptotic activity were successfully evaluated. Remarkably, the conjugation of this CD44 inhibitor to the nanodevice generated a reduction of the dosis required to achieve a significant therapeutic effect.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/anticancer therapycluster of differentiation 44hyaluronic acidmolecular dynamics simulationsnanomedicineselective releasetetrahydroisoquinolineHyaluronic AcidCell MovementBinding SitesNeovascularization, PathologicNeoplastic ProcessesNeoplasmsTumor MicroenvironmentDrug LiberationCell SurvivalSelective Anticancer Therapy Based on a HA-CD44 Interaction Inhibitor Loaded on Polymeric Nanoparticles.research article35456622open accessMicroambiente tumoralLiberación de fármacosMovimiento celularNeoplasiasNeovascularización patológicaProcesos neoplásicosSitios de uniónSupervivencia celularÁcido hialurónico10.3390/pharmaceutics14040788PMC9032636https://www.mdpi.com/1999-4923/14/4/788/pdf?version=1649758834https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032636/pdf